Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

954 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension.
Vermeire S, Sands BE, Tilg H, Tulassay Z, Kempinski R, Danese S, Bunganič I, Nitcheu J, Santo J, Scherrer D, Biguenet S, Ehrlich HJ, Steens JM, Gineste P, Sandborn WJ. Vermeire S, et al. Among authors: sandborn wj. Lancet Gastroenterol Hepatol. 2022 Nov;7(11):1024-1035. doi: 10.1016/S2468-1253(22)00233-3. Epub 2022 Sep 6. Lancet Gastroenterol Hepatol. 2022. PMID: 36075249 Clinical Trial.
Intravenous azathioprine in severe ulcerative colitis: a pilot study.
Mahadevan U, Tremaine WJ, Johnson T, Pike MG, Mays DC, Lipsky JJ, Sandborn WJ. Mahadevan U, et al. Among authors: sandborn wj. Am J Gastroenterol. 2000 Dec;95(12):3463-8. doi: 10.1111/j.1572-0241.2000.03362.x. Am J Gastroenterol. 2000. PMID: 11151878 Clinical Trial.
An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial.
Sandborn WJ, Feagan BG, Hanauer SB, Present DH, Sutherland LR, Kamm MA, Wolf DC, Baker JP, Hawkey C, Archambault A, Bernstein CN, Novak C, Heath PK, Targan SR; CDP571 Crohn's Disease Study Group. Sandborn WJ, et al. Gastroenterology. 2001 May;120(6):1330-8. doi: 10.1053/gast.2001.24042. Gastroenterology. 2001. PMID: 11313302 Clinical Trial.
The fate of low grade dysplasia in ulcerative colitis.
Ullman TA, Loftus EV Jr, Kakar S, Burgart LJ, Sandborn WJ, Tremaine WJ. Ullman TA, et al. Among authors: sandborn wj. Am J Gastroenterol. 2002 Apr;97(4):922-7. doi: 10.1111/j.1572-0241.2002.05610.x. Am J Gastroenterol. 2002. PMID: 12008669
Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
Sandborn WJ, Sands BE, Wolf DC, Valentine JF, Safdi M, Katz S, Isaacs KL, Wruble LD, Katz J, Present DH, Loftus EV Jr, Graeme-Cook F, Odenheimer DJ, Hanauer SB. Sandborn WJ, et al. Aliment Pharmacol Ther. 2003 Jun 1;17(11):1355-64. doi: 10.1046/j.1365-2036.2003.01589.x. Aliment Pharmacol Ther. 2003. PMID: 12786629 Clinical Trial.
State of the art: IBD therapy and clinical trials in IBD.
Isaacs KL, Lewis JD, Sandborn WJ, Sands BE, Targan SR. Isaacs KL, et al. Among authors: sandborn wj. Inflamm Bowel Dis. 2005 Nov;11 Suppl 1:S3-12. doi: 10.1097/01.mib.0000184852.84558.b2. Inflamm Bowel Dis. 2005. PMID: 16254481 Review.
954 results